- Home
- FDBC vs NGNE Comparison
FDBC vs NGNE Comparison
Compare FDBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- NGNE
- Stock Information
- Founded
- FDBC 1902
- NGNE 2003
- Country
- FDBC United States
- NGNE United States
- Employees
- FDBC N/A
- NGNE N/A
- Industry
- FDBC Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FDBC Finance
- NGNE Health Care
- Exchange
- FDBC Nasdaq
- NGNE Nasdaq
- Market Cap
- FDBC 238.0M
- NGNE 251.9M
- IPO Year
- FDBC N/A
- NGNE N/A
- Fundamental
- Price
- FDBC $48.59
- NGNE $20.09
- Analyst Decision
- FDBC
- NGNE Strong Buy
- Analyst Count
- FDBC 0
- NGNE 7
- Target Price
- FDBC N/A
- NGNE $41.86
- AVG Volume (30 Days)
- FDBC 9.6K
- NGNE 240.1K
- Earning Date
- FDBC 07-23-2025
- NGNE 08-08-2025
- Dividend Yield
- FDBC 3.29%
- NGNE N/A
- EPS Growth
- FDBC 32.34
- NGNE N/A
- EPS
- FDBC 3.75
- NGNE N/A
- Revenue
- FDBC $81,316,000.00
- NGNE $925,000.00
- Revenue This Year
- FDBC N/A
- NGNE N/A
- Revenue Next Year
- FDBC N/A
- NGNE N/A
- P/E Ratio
- FDBC $12.96
- NGNE N/A
- Revenue Growth
- FDBC 15.07
- NGNE N/A
- 52 Week Low
- FDBC $37.00
- NGNE $6.88
- 52 Week High
- FDBC $61.21
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- FDBC 71.22
- NGNE 57.57
- Support Level
- FDBC $43.55
- NGNE $14.65
- Resistance Level
- FDBC $49.43
- NGNE $18.21
- Average True Range (ATR)
- FDBC 1.25
- NGNE 1.84
- MACD
- FDBC 0.71
- NGNE 0.03
- Stochastic Oscillator
- FDBC 91.53
- NGNE 80.24
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.